AstraZeneca's Tagrisso, or osimertinib, which is being developed as a first-line treatment for patients with metastatic epidermal growth factor receptor mutation-positive non-small cell lung cancer, was given breakthrough therapy status by the FDA.
FDA gives breakthrough designation to AstraZeneca's Tagrisso
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.